ArcaArca
Dashboard
All boards
Loading...
PatientsTasksProgram PerformanceRegistry
Settings
  1. Home
  2. Tumor Boards
  3. Board
  4. Session

GI Oncology Tumor Board

Sun, Apr 19, 2026 · 12:00 · Conference Room B

In Progress
0
Case 1 of 6 · 0 discussed

0 of 6 presented

Davis, Gloria

MRN-001032·54y

Presenting

Dr. Coordinator

Pancreatic Ductal Adenocarcinoma·Stage IB
BiomarkersER—/PR—/HER2—
Histology—
Path StagepT1N1M0
MarginsClose (1.9mm at lateral margin)
Key Labs—
Prior TxPostmenopausal
Labs not resulted

Highlighted Path

Davis, Gloria

Stage IB · KRAS G12D, CA 19-9 3764 U/mL, BRCA wild-type

NCCN Breast Cancer

v4.2025

Breast Cancer
DCIS (Non-invasive)
Stage 0
Lumpectomy → ± WBRT → ± Endocrine
Mastectomy → ± Endocrine
Invasive
Early Stage (I–IIA)
HR+/HER2−
Surgery → Endocrine ± Chemo
HR+/HER2+
Surgery → TCH(P) → Endocrine
HR−/HER2+
Surgery → TCH(P)
Triple Negative
Surgery → AC-T
Locally Advanced (IIB–III)
HR+/HER2−
Neoadjuvant Chemo → Surgery → Endocrine
HER2+
Neoadjuvant TCHP → Surgery → HER2 maintenance
Triple Negative
Neoadjuvant Chemo + Pembrolizumab → Surgery
Metastatic (IV)
HR+/HER2−
Endocrine + CDK4/6i (1L)
HER2+
Taxane + Trastuzumab + Pertuzumab (1L)
Triple Negative
Chemo + Pembrolizumab (PD-L1+)
Patient pathway Other pathways
12 treatment approaches mapped
Case 1 of 600:00
Clinical question

Case under preparation for upcoming board

Loading guidelines…
Owner
0 recommendations confirmed